Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2

Brooks, P., Emery, P., Evans, J. F., Fenner, H., Hawkey, C. J., Patrono, C., Smolen, J., Breedveld, F., Day, R., Dougados, M., Ehrich, E. W., Gijon-Baños, J., Kvien, T. K., Van Rijswijk, M. H., Warner, T. and Zeidler, H. (1999). Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. In: , , (779-788). . doi:10.1093/rheumatology/38.8.779


Author Brooks, P.
Emery, P.
Evans, J. F.
Fenner, H.
Hawkey, C. J.
Patrono, C.
Smolen, J.
Breedveld, F.
Day, R.
Dougados, M.
Ehrich, E. W.
Gijon-Baños, J.
Kvien, T. K.
Van Rijswijk, M. H.
Warner, T.
Zeidler, H.
Title of paper Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2
Journal name Rheumatology (Oxford, England)   Check publisher's open access policy
Publication Year 1999
Sub-type Fully published paper
DOI 10.1093/rheumatology/38.8.779
Open Access Status Not yet assessed
ISSN 1462-0324
Volume 38
Issue 8
Start page 779
End page 788
Total pages 10
Language eng
Abstract/Summary The International Consensus Meeting on the Mode of Action of COX-2 Inhibition (ICMMAC) brought together 17 international experts in arthritis, gastroenterology and pharmacology on 5 6 December 1997. The meeting was convened to provide a definition of COX-2 specificity and to consider the clinical relevance of COX-2-specific agents. These compounds are a new class of drugs that specifically inhibit the enzyme COX-2 while having no effect on COX-1 across the whole therapeutic dose range. The objectives of the meeting were to review the currently available data regarding the roles and biology of COX-1 and COX-2, and to foster a consensus definition on COX-2 specificity. At the present time, no guidelines exist for the in vitro and in vivo assessment of COX specificity, and it was felt that consensus discussion might clarify some of these issues. The meeting also reviewed recent clinical data on COX-2-specific inhibitors. The following article reflects discussion at this meeting and provides a consensus definition of COX-2-specific inhibitors.
Subjects 2745 Rheumatology
2736 Pharmacology (medical)
Q-Index Code E1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Conference Paper
Sub-type: Fully published paper
Collection: Scopus Import - Archived
 
Versions
Version Filter Type
Citation counts: Scopus Citation Count Cited 148 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 15 Dec 2017, 09:28:53 EST